Primary Biliary Cholangitis

[41] Harms MH(2021)Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis Aliment Pharmacol Ther 53 2171-743.e6

[42] Gao Y(2018)A placebo-controlled trial of bezafibrate in primary biliary cholangitis N Engl J Med 378 283-1343

[43] Goldstein J(2016)Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes Aliment Pharmacol Ther 43 734-726

[44] Levy C(2021)Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial Gastroenterology 160 1335-123

[45] Honda A(2021)Safety of fibrates in cholestatic liver diseases Liver Int 41 716-85

[46] Gallucci GM(2017)Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study Lancet Gastroenterol Hepatol 2 112-720

[47] Sorda JA(2022)Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis Liver Int 42 75-49.e5

[48] Soret PA(2022)Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis J Hepatol 76 715-877

[49] Corpechot C(2006)Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 1338-1367

[50] Cheung AC(2014)Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study Gastroenterology 147 871-121

[41] Harms MH(2021)Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis Aliment Pharmacol Ther 53 2171-743.e6

[42] Gao Y(2018)A placebo-controlled trial of bezafibrate in primary biliary cholangitis N Engl J Med 378 283-1343

[43] Goldstein J(2016)Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes Aliment Pharmacol Ther 43 734-726

[44] Levy C(2021)Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial Gastroenterology 160 1335-123

[45] Honda A(2021)Safety of fibrates in cholestatic liver diseases Liver Int 41 716-85

[46] Gallucci GM(2017)Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study Lancet Gastroenterol Hepatol 2 112-720

[47] Sorda JA(2022)Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis Liver Int 42 75-49.e5

[48] Soret PA(2022)Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis J Hepatol 76 715-877

[49] Corpechot C(2006)Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 1338-1367

[50] Cheung AC(2014)Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study Gastroenterology 147 871-121